Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Bruder, Joseph T ^a   Semenova, Elena ^a   Chen, Ping ^a   Limbach, Keith ^b   Patterson, Noelle B ^b   Stefaniak, Maureen E ^b   Konovalova, Svetlana ^a   Thomas, Charlie ^a,d   Hamilton, Melissa ^a,e   King, C Richter ^a,f   Richie, Thomas L ^b   Doolan, Denise L ^b,c  

^a GENVEC INC   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MEDIMMUNE   (United States)

^f INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS 5 NEUTRALIZING ANTIBODY; ADENOVIRUS VECTOR; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; CAPSID PROTEIN; HEXON CAPSID PROTEIN, ADENOVIRUS; VIRUS VACCINE;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PROTEIN MODIFICATION; PROTEIN STRUCTURE; RABBIT; T LYMPHOCYTE; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE VECTOR; GENETIC ENGINEERING; GENETICS; HUMAN; IMMUNOLOGY; SERODIAGNOSIS; TRANSGENE;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS TYPE 5; MUS; ORYCTOLAGUS CUNICULUS; RODENTIA;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; CAPSID PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RABBITS; T-LYMPHOCYTES; TRANSGENES; VIRAL VACCINES;

EID: 84859345005     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033920     Document Type: Article

References (64)

1. Brough DE, Lizonova A, Hsu C, Kulesa VA, Kovesdi I, (1996) A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 70: 6497-6501.
2. Rasmussen H, Rasmussen C, Lempicki M, Durham R, Brough D, et al. (2002) TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 9: 951-957.
3. Shiver JW, Emini EA, (2004) Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55: 355-372.
4. Lasaro MO, Ertl HC, (2009) New insights on adenovirus as vaccine vectors. Mol Ther 17: 1333-1339.
5. Bruder JT, Angove E, Limbach KJ, Richie TL, (2010) Molecular Vaccines for Malaria. Human Vaccines 6:1: 1-25.
6. Jacobs SC, Stephenson JR, Wilkinson GW, (1992) High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model. J Virol 66: 2086-2095.
7. Xiang ZQ, Yang Y, Wilson JM, Ertl HC, (1996) A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219: 220-227.
8. Lubeck MD, Natuk R, Myagkikh M, Kalyan N, Aldrich K, et al. (1997) Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 3: 651-658.
9. Rodrigues EG, Zavala F, Eichinger D, Wilson JM, Tsuji M, (1997) Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J Immunol 158: 1268-1274.
10. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, et al. (2003) Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424: 681-684.
11. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, et al. (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
12. Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, et al. (2002) Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20: 1039-1045.
13. Tan Y, Hackett NR, Boyer JL, Crystal RG, (2003) Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen. Hum Gene Ther 14: 1673-1682.
14. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, et al. (2004) Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 173: 6357-6365.
15. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, et al. (2005) Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404-5410.
16. Worgall S, Krause A, Rivara M, Hee KK, Vintayen EV, et al. (2005) Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest 115: 1281-1289.
17. Ophorst OJ, Radosevic K, Havenga MJ, Pau MG, Holterman L, et al. (2006) Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun 74: 313-320.
18. Rodrigues EG, Claassen J, Lee S, Wilson JM, Nussenzweig RS, et al. (2000) Interferon-gamma-independent CD8+ T cell-mediated protective anti-malaria immunity elicited by recombinant adenovirus. Parasite Immunol 22: 157-160.
19. Sridhar S, Reyes-Sandoval A, Draper SJ, Moore AC, Gilbert SC, et al. (2008) Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J Virol 82: 3822-3833.
20. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, et al. (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194: 1638-1649.
21. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
22. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
23. Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, et al. (2010) The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med 181: 1407-1417.
24. Sedegah M, Kim Y, Peters B, McGrath S, Ganeshan H, et al. (2010) Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein. Malar J 9: 241.
25. Sedegah M, Tamminga C, McGrath S, House B, Ganeshan H, et al. (2011) Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One 6: e24586.
26. Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, et al. (2011) Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One 6: e25868.
27. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, et al. (2003) Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77: 8263-8271.
28. Cheng C, Gall JG, Kong WP, Sheets RL, Gomez PL, et al. (2007) Mechanism of Ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog 3: e25.
29. Thorner AR, Vogels R, Kaspers J, Weverling GJ, Holterman L, et al. (2006) Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol 44: 3781-3783.
30. Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, et al. (2004) Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. Aids 18: 1213-1216.
31. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, et al. (2005) Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174: 7179-7185.
32. Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, et al. (2005) Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 79: 9694-9701.
33. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, et al. (2003) Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77: 6305-6313.
34. Hierholzer JC, Stone YO, Broderson JR, (1991) Antigenic relationships among the 47 human adenoviruses determined in reference horse antisera. Arch Virol 121: 179-197.
35. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, et al. (2004) Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172: 6290-6297.
36. Farina SF, Gao GP, Xiang ZQ, Rux JJ, Burnett RM, et al. (2001) Replication-defective vector based on a chimpanzee adenovirus. J Virol 75: 11603-11613.
37. Fitzgerald JC, Gao GP, Reyes-Sandoval A, Pavlakis GN, Xiang ZQ, et al. (2003) A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170: 1416-1422.
38. Pinto AR, Fitzgerald JC, Giles-Davis W, Gao GP, Wilson JM, et al. (2003) Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol 171: 6774-6779.
39. Xiang Z, Gao G, Reyes-Sandoval A, Cohen CJ, Li Y, et al. (2002) Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 76: 2667-2675.
40. Ophorst OJ, Kostense S, Goudsmit J, De Swart RL, Verhaagh S, et al. (2004) An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 22: 3035-3044.
41. Hensley SE, Cun AS, Giles-Davis W, Li Y, Xiang Z, et al. (2007) Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol Ther 15: 393-403.
42. Rux JJ, Burnett RM, (2004) Adenovirus structure. Hum Gene Ther 15: 1167-1176.
43. Hong SS, Habib NA, Franqueville L, Jensen S, Boulanger PA, (2003) Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors. J Virol 77: 10366-10375.
44. Norrby E, (1969) The structural and functional diversity of Adenovirus capsid components. J Gen Virol 5: 221-236.
45. Gall J, Kass-Eisler A, Leinwand L, Falck-Pedersen E, (1996) Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 70: 2116-2123.
46. Gall JG, Crystal RG, Falck-Pedersen E, (1998) Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J Virol 72: 10260-10264.
47. Youil R, Toner TJ, Su Q, Chen M, Tang A, et al. (2002) Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther 13: 311-320.
48. Rux JJ, Kuser PR, Burnett RM, (2003) Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J Virol 77: 9553-9566.
49. Roberts MM, White JL, Grutter MG, Burnett RM, (1986) Three-dimensional structure of the adenovirus major coat protein hexon. Science 232: 1148-1151.
50. Rux JJ, Burnett RM, (2000) Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. Mol Ther 1: 18-30.
51. Roy S, Shirley PS, McClelland A, Kaleko M, (1998) Circumvention of immunity to the adenovirus major coat protein hexon. J Virol 72: 6875-6879.
52. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, et al. (2006) Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441: 239-243.
53. Toogood CIA, Crompton J, Hay RT, (1992) Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J Gen Virol 73: 1429-1435.
54. Wohlfart C, (1988) Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J Virol 62: 2321-2328.
55. Bruder JT, Stefaniak ME, Patterson NB, Chen P, Konovalova S, et al. (2010) Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth. Vaccine 28: 3201-3210.
56. Potocnjak P, Yoshida N, Nussenzweig RS, Nussenzweig V, (1980) Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection*. The Journal of Experimental Medicine 151: 1504-1513.
57. Egan JE, Weber JL, Ballou WR, Hollingdale MR, Majarian WR, et al. (1987) Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science 236: 453-456.
58. Charoenvit Y, Mellouk S, Cole C, Bechara R, Leef MF, et al. (1991) Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. J Immunol 146: 1020-1025.
59. Wang R, Charoenvit Y, Corradin G, Porrozzi R, Hunter RL, et al. (1995) Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J Immunol 154: 2784-2793.
60. Tsuji M, Zavala F, (2003) T cells as mediators of protective immunity against liver stages of Plasmodium. Trends Parasitol 19: 88-93.
61. Doolan DL, Martinez-Alier N, (2006) Immune response to pre-erythrocytic stages of malaria parasites. Curr Mol Med 6: 169-185.
62. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, et al. (2007) Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654-4663.
63. Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, et al. (2003) Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 41: 5046-5052.
64. Roederer M, Nozzi JL, Nason MC, (2011) SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79: 167-174.